RVTY · 8-K · 20260804PR000022

Revenue Performance and Mix

REVVITY, INC. · 2026-08-04 · Importance 49 · Surprise 32 · Contradicted

Second-quarter 2026 reported revenue increased to $730 million from $720 million year over year, while pro forma revenue rose 4% to $711 million from $681 million. Life Sciences revenue declined 2% pro forma and 3% organically to $359 million, while Diagnostics revenue increased 12% pro forma and 11% organically to $371 million. Diagnostics therefore represented approximately 52% of reported segment revenue, up from approximately 49% a year earlier. For the first six months, reported revenue increased to $1.441 billion from $1.385 billion, driven by Diagnostics revenue growth of 12% to $720 million while Life Sciences revenue increased 2% to $721 million.

Key facts

• Pro forma revenue growth (quarter): 4%. source
• Pro forma organic revenue growth (quarter): 3%. source
• Pro forma organic revenue growth from continuing operations for the six months ended July 5, 2026: 4% (pro forma revenue growth 7% less foreign exchange 2% and acquisitions 1%). source
• Revenue for the second quarter ended July 5, 2026: $730 million. source
• Pro forma revenue for the second quarter: $711 million. source
• Three months ended July 5, 2026 revenue (As Reported) in condensed statement: $729,688 (thousands). source
• Three months ended July 5, 2026 pro forma revenue in condensed statement: $711,109 (thousands). source
• Six months ended July 5, 2026 total revenue (As Reported): $1,440,806 (thousands). source

Impact estimates